 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Eli Lilly and Company |
| Street 1: | Lilly Corporate Center |
| Street 2: | |
| City: | Indianapolis |
| Province: | Indiana |
| Post Code: | 46285 |
| Country: | United States of America |
| Phone: | 41223060394 |
| Email: | karen.vdw@lilly.com |
| Web Site: | http://www.lilly.com, http://www.lillymdr-tb.com/ |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Company |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| Recognizing that MDR-TB cannot be halted by medicine alone, Lilly created the Lilly MDR-TB Partnership in 2003. This public-private initiative mobilizes over 20 partners on five continents to tackle the scourge of TB and MDR-TB. Eli Lilly and Company is contributing US$ 120 million in cash, medicines, advocacy tools and technology to focus global resources on prevention, diagnosis and treatment of TB and MDR-TB. An additional US$ 15 million was given to the Lilly TB Drug Discovery Initiative; a nonprofit with the goal of accelerating the discovery of new drugs to treat TB by bringing together specialists from around the world. The company has made this investment to ensure that thousands of MDR-TB patients receive the care and medication they need to combat this disease. |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 6 - 10 |
| Number of part-time staff who are directly involved with TB: | 1 - 5 |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| What is your organization's annual budget (USD) dedicated to TB? | $1 MIL-$10 MIL |
| How did you hear about the Stop TB Partnership: | Other partners |
| Why do you wish join the Stop TB Partnership: | Technical assistance and advice |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| In our four focus countries (China, India, Russia and South Africa), we work closely with a number of local partners including the national Ministries of Health to support the national TB control plan. | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which WHO region is the main focus of your work: | Global |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China India Russian Federation South Africa Switzerland United States of America |
Specializations | |
|
Advocacy, communication and social mobilization Funding Provision of drugs, diagnostics and commodities Research and Development |
Specializations in Countries | |
| Advocacy, communication and social mobilization | China |
| Advocacy, communication and social mobilization | India |
| Advocacy, communication and social mobilization | Russian Federation |
| Advocacy, communication and social mobilization | South Africa |
| Funding | China |
| Funding | India |
| Funding | Russian Federation |
| Funding | South Africa |
| Funding | Switzerland |
| Funding | United States of America |
| Provision of drugs, diagnostics and commodities | China |
| Provision of drugs, diagnostics and commodities | India |
| Provision of drugs, diagnostics and commodities | Russian Federation |
| Provision of drugs, diagnostics and commodities | South Africa |
| Research and Development | United States of America |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
DOTS Expansion and Enhancement: see www.lillymdr-tb.com Drug-Resistant TB: see www.lillymdr-tb.com Operational Research: see www.lillymdr-tb.com |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | |
| Last updated: | October 3, 2012 |